Moreover, we evaluated not only liver, metabolic, and inflammatory parameters but also measured FGF-19 levels, which is believed to play a pivotal role in the pathogenesis of NAFLD/NASH and a promising treatment modality. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.